[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-343236-105":59,"doc-detail-343236-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","her2-low-gastric-cancer-is-the-subgroup-targetable-review","HER2-low gastric cancer: is the subgroup targetable? - Review","","Therapeutic advances in anti-HER2 treatment have expanded from conventional HER2-positive gastric cancer to include HER2-low and HER2-ultralow subgroups, yet the targetability of HER2-low gastric cancer remains unclear. Further research is needed to define its clinicopathological characteristics, specific gene alterations, and distinct tumor immune microenvironment, and to compare these with HER2-positive and HER2-negative disease. The review discusses the role of HER2-targeting antibody-drug conjugates and emerging strategies, including bispecific T-cell engager antibodies, immunomodulatory agents, and potential HER2 re-categorization approaches using IHC/FISH and ERRB2 copy number or protein expression measurements.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/her2-low-gastric-cancer-is-the-subgroup-targetable-review/343236/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/her2-low-gastric-cancer-is-the-subgroup-targetable-review/343236.png","ImageObject",300,407,{"name":92,"@type":93},"Miles","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why is the targetability of HER2-low gastric cancer still uncertain?","Question",{"text":113,"@type":114},"Unlike HER2-positive disease, HER2-low gastric cancer has not shown clear benefit from anti-HER2 therapy for decades. The review highlights that its clinicopathological features and tumor immune microenvironment require further definition and comparison.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What evidence from the ToGA trial shaped the early view of HER2-low as untargetable?",{"text":118,"@type":114},"Post hoc analysis reported improved overall survival for HER2-positive patients treated with trastuzumab plus chemotherapy, while no similar trend was observed for HER2 IHC 0/1+ with FISH-positive disease. A significant interaction was also noted for trastuzumab efficacy across these groups.",{"name":120,"@type":111,"acceptedAnswer":121},"How do HER2-targeting antibody-drug conjugates make HER2-low gastric cancer potentially actionable?",{"text":122,"@type":114},"The review explains that ADC payloads are internalized into HER2-positive cells and exert bystander killing on nearby HER2-low and HER2-nonexpressing tumor cells. ADC-related effects may also modulate the tumor microenvironment and improve immunotherapy efficacy in “immuno-cold” gastric cancer.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},343236,1790182554,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},13056703019404,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","REVIEW  \nHER2-low gastric cancer: is the subgroup targetable?  \nK. Shimozaki1, 2, S. Fukuoka1, A. Ooki1 􀀁 & K. Yamaguchi1  \n1Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo; 2Keio Cancer Center, Keio University School of Medicine, Tokyo, Japan  \nAvailable online xxx  \nTherapeutic developments in the targeting of human epidermal growth factor receptor 2 (HER2)-expressing gastric cancer have followed the dramatic success of HER2-expressing breast cancer treatment, which has facilitated the expansion of indications for anti-HER2 agents to include not only conventional HER2-positive breast cancer, but also HER2-low and HER2-ultralow subgroups. The targetability of HER2-low gastric cancer, however, has yet to be established. Hence, further studies are needed to comprehensively understand the clinicopathological features, speciﬁc gene alterations, and distinct tumor immune microenvironment of HER2-low gastric cancer and compare them with those for HER2-positive or -negative gastric cancer. Antibodyedrug conjugates for HER2 play an important role in making HER2-low gastric cancer targetable. In this context, a deeper understanding of the novel anti-HER2 agents, including antibodyedrug conjugates, bispeciﬁc T-cell engager antibodies, and a combination of these agents, as well as new forms of immunomodulatory agents are also required. Redeﬁning and re-categorizing HER2 status through not only immunohistochemistry/ﬂuorescence in situ hybridization but also evaluating ERRB2 copy number gain or protein overexpression levels measured using DNA or RNA sequencing might be helpful for identifying populations with HER2-expressing tumors who would ideally beneﬁt from anti-HER2 treatment. The current paper reviewed recent clinical trials, focusing particularly on HER2-low gastric cancer together with basic/ translational ﬁndings, and discuss perspectives on further therapeutic development in the treatment of this distinct subgroup.  \nKey words: HER2, trastuzumab deruxtecan, antibodyedrug conjugate, bispeciﬁc antibody, gastric cancer  \nINTRODUCTION  \nApproximately 15%-20% of patients with advanced gastric and gastroesophageal junctional cancers (AGCs) exhibit overexpression or ampliﬁcation of human epidermal growth factor receptor 2 (HER2, also known as ERBB2), a transmembrane tyrosine kinase receptor encoded by the ERRB2 gene located in chromosome 17q12, which has been established as an important biomarker and key driver of tumorigenesis in AGC.1 Similar to that in breast cancer, HER2 status of AGCs is typically determined via immunohistochemistry (IHC) and in situ hybridization (ISH) . The ToGA trial found that trastuzumab, a monoclonal antibody targeting HER2, signiﬁcantly improved overall survival (OS) when combined with chemotherapy for HER2-positive AGC,2 deﬁned as HER2 IHC 3þ or 2þ/ﬂuorescence in situ  \n*Correspondence to: Dr Akira Ooki, Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Ariake 3-8-3, Koto-ku, Tokyo, Japan. Tel: þ81-3-3520-0111; Fax:þ81-3-3520-0111  \nE-mail: [akira.oki@jfcr.or.jp](akira.oki@jfcr.or.jp) (A. Ooki).  \n2059-7029/© 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology. This is an open access article under the CC BY-NC-ND license ([http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/)).  \nhybridization (FISH)-positive, by inducing direct cytostatic activity and antibody-dependent cellular cytotoxicity (ADCC), which inhibited HER2-mediated signaling and prevented the cleavage of the extracellular domain (ECD) of HER2 .3 The success of the ToGA trial promoted the use of trastuzumab plus chemotherapy as the ﬁrst-line treatment of HER2-positive AGCs worldwide.  \nAmong the subgroups of HER2-positive AGCs, ‘HER2-low’AGCs, which are usually deﬁned as IHC 2þ and FISHnegative or IHC 1þ in ac","cbCaihYEb3fY7y3M","https://ap.wps.com/l/cbCaihYEb3fY7y3M","pdf",772539,11,"English","# Review overview\n## Clinical rationale for HER2-low targeting\n## Need for clinicopathological and molecular clarification\n# HER2 status and testing in gastric cancer\n## IHC/ISH-based HER2 categorization\n## Impact of ToGA trial findings\n# Emergence of HER2-targeting antibody-drug conjugates\n## ADC mechanisms and bystander killing\n## Modulation of tumor microenvironment and immunotherapy relevance\n# Future directions\n## HER2 redefinition and population selection\n## Future therapeutic development for the HER2-low subgroup","[{\"question\":\"Why is the targetability of HER2-low gastric cancer still uncertain?\",\"answer\":\"Unlike HER2-positive disease, HER2-low gastric cancer has not shown clear benefit from anti-HER2 therapy for decades. The review highlights that its clinicopathological features and tumor immune microenvironment require further definition and comparison.\"},{\"question\":\"What evidence from the ToGA trial shaped the early view of HER2-low as untargetable?\",\"answer\":\"Post hoc analysis reported improved overall survival for HER2-positive patients treated with trastuzumab plus chemotherapy, while no similar trend was observed for HER2 IHC 0/1+ with FISH-positive disease. A significant interaction was also noted for trastuzumab efficacy across these groups.\"},{\"question\":\"How do HER2-targeting antibody-drug conjugates make HER2-low gastric cancer potentially actionable?\",\"answer\":\"The review explains that ADC payloads are internalized into HER2-positive cells and exert bystander killing on nearby HER2-low and HER2-nonexpressing tumor cells. ADC-related effects may also modulate the tumor microenvironment and improve immunotherapy efficacy in “immuno-cold” gastric cancer.\"}]","HER2-low gastric cancer: is the subgroup targetable? - Review | PDF",1790050380,28,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b8d36ae0be6ae7817b44b85189f9fa62.webp",983,1269,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aca026f8ff975ce10fda2ba0ebdc2658.webp",982,1268,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/44d5eb18adfb305d8797518b88fee221.webp",981,1266,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b41f8febacf33b0daf19020503b44e64.webp",980,1265]